Procter & Gamble Health board reviews Q2 FY27 financial results

Procter & Gamble Health Limited is scheduled to consider its unaudited Q2 FY27 and first-half results at a board meeting on November 2, 2026. The release matters because the company enters the September quarter after reporting revenue growth of 7.37% year-on-year and a 45.29% rise in reported net profit in Q1 FY27.

Why is Procter & Gamble Health reviewing Q2 FY27 results today?

Procter & Gamble Health Limited will consider and approve unaudited financial results for the quarter and half year ended September 30, 2026, at its November 2 board meeting. The Q2 FY27 period covers July 1 to September 30, 2026, and the board meeting is the next scheduled earnings event for the company.

The company operates in the pharma and health segment and sells vitamins, minerals and supplements through pharmacy and prescription channels. Its portfolio includes brands such as Neurobion, Livogen, Nasivion and Seven Seas. The quarterly update will provide the first reported view of how the business performed during the first half of FY27.

The available information indicates that the board meeting is intended to review unaudited results under the applicable Securities and Exchange Board of India regulations. At the time of the supplied update, the Q2 figures had not been filed. Therefore, revenue, profitability, margins and any management commentary for the September quarter should not be assumed before the company releases its results.

Some earlier information noted that no board-meeting intimation had been filed as of September 11, 2026. The subsequent event information identifies November 2 as the date on which the board will consider the results. This sequence underlines why exchange filings and company disclosures are the relevant source for confirming quarterly earnings schedules.

What did PGHL report in the June 2026 quarter?

PGHL reported Q1 FY27 revenue of ₹363.71 crore, up 7.37% from ₹338.74 crore in the June 2025 quarter. Revenue was down 1.82% sequentially from the preceding March 2026 quarter, reflecting the comparison with a stronger prior quarter.

Reported net profit rose 45.29% year-on-year to ₹96.15 crore from ₹66.18 crore. It was also 1.64% higher than ₹94.60 crore in the preceding quarter. Gross profit stood at ₹99 crore, up 17.15% year-on-year but down 23.15% sequentially, according to the provided quarterly data.

However, the reported profit increase included an exceptional gain of ₹31.80 crore from the sale of PGHL's Worli office premises. The property was sold for ₹33.34 crore against a carrying value of ₹1.54 crore. This one-time item is important when comparing reported profit with the underlying operating performance.

After excluding the exceptional gain, adjusted profit after tax was approximately ₹64.35 crore. The supplied analysis states this was about 2.8% lower year-on-year and about 32% lower quarter-on-quarter. Profit before exceptional items and tax was ₹97.32 crore, equivalent to 26.8% of revenue, compared with 26.2% a year earlier and about 36% in the seasonally stronger March 2026 quarter.

What is the comparison base for PGHL's September quarter?

PGHL's Q2 FY27 results will be compared with revenue of ₹325 crore and profit of ₹89 crore in the September 2025 quarter. These figures establish the year-on-year base for the July-to-September 2026 period, but they do not indicate what the company will report for Q2 FY27.

The quarterly sales history shows that PGHL reported sales of ₹325 crore in September 2025, followed by ₹374 crore in December 2025 and ₹370 crore in March 2026. Sales were ₹364 crore in June 2026 in the rounded quarterly series. Operating profit in these four quarters was ₹120 crore, ₹110 crore, ₹136 crore and ₹100 crore, respectively.

This pattern shows that the company has experienced quarter-to-quarter movement in both sales and operating profit. The March 2026 quarter had a higher operating-profit figure than the June 2026 quarter, which is relevant when assessing sequential comparisons. It also explains why the supplied analysis described the March quarter as seasonally elevated.

No verified analyst estimate for PGHL's Q2 FY27 revenue or profit was included in the provided information. As a result, no numerical forecast is used for the September quarter. The reported figures and the September 2025 base remain the factual benchmarks until the company files its financial results.

How could the Q2 update affect investors and operations?

PGHL's Q2 update will allow investors to separate reported earnings from operating performance after the one-time property-sale gain lifted Q1 FY27 net profit. The June-quarter revenue growth was positive, but the exceptional item means the reported 45.29% profit growth does not by itself measure the underlying earnings trend.

Investors will be able to review revenue growth, gross profit, operating-profit trends and net profit alongside the September 2025 comparison base. The results will also show whether the June-quarter movement in operating profitability continued, changed or reversed during the July-to-September period.

For the company's pharmacy and prescription-channel operations, the results can provide a financial update on the scale of sales across its health portfolio. But the supplied information does not include product-level sales, volume growth, pricing details or region-wise performance. Those details should only be assessed if they are disclosed with the results or in accompanying management communication.

The broader pharmaceutical and health-products context is also relevant because PGHL's business is measured through both revenue growth and profitability. The available data show that sales increased year-on-year in Q1 FY27, while adjusted profit was lower after removing the exceptional gain. The September-quarter disclosure will provide the next reported comparison for these measures.

Conclusion

PGHL's November 2 board meeting is the scheduled point at which the company will consider its Q2 FY27 and first-half unaudited financial results. The key reference points are Q1 FY27 revenue of ₹363.71 crore, reported net profit of ₹96.15 crore and the September 2025 base of ₹325 crore in revenue and ₹89 crore in profit. The June-quarter reported profit also included a ₹31.80 crore exceptional gain from an office-premises sale.

The next item to watch is PGHL's exchange filing of the September-quarter results and any accompanying disclosure on revenue, profitability and exceptional items. Until that filing is available, there is no verified public revenue or profit estimate for Q2 FY27 in the supplied information.